Yamashita Y, Akiyama T, Mizusawa N, Yoshimoto K, Goto M
Department of Oral and Maxillofacial Surgery, Saga Medical School, 5-1-1 Nabeshima, Saga 849-8501, Japan.
Int J Oral Maxillofac Surg. 2007 Apr;36(4):365-9. doi: 10.1016/j.ijom.2006.08.007. Epub 2006 Oct 18.
Hyperparathyroidism-jaw tumour (HPT-JT) syndrome is characterized by parathyroid tumours as well as by ossifying fibromas of the mandible and maxilla, renal cysts, or Wilms' tumours. Recently, the gene responsible for HPT-JT syndrome has been identified as the HRPT2 tumour suppressor gene. In an 18-year-old male, a tumour in the maxilla was first diagnosed as an ossifying fibroma. During biochemical screening before surgery, the patient received a diagnosis of primary hyperparathyroidism. Neck computed tomography scanning showed a parathyroid tumour. Surgical excisions to remove the jaw tumour and parathyroid adenoma were performed. The postoperative course has been uneventful and a follow up at 2 years revealed no evidence of recurrence. The HRPT2 germline mutation of 39delC was detected in the proband, but not in his unaffected parents. These results suggested that the germline mutation occurred de novo.
甲状旁腺功能亢进-颌骨肿瘤(HPT-JT)综合征的特征是甲状旁腺肿瘤以及下颌骨和上颌骨的骨化纤维瘤、肾囊肿或威尔姆斯瘤。最近,已确定导致HPT-JT综合征的基因是HRPT2肿瘤抑制基因。一名18岁男性患者,上颌骨肿瘤最初被诊断为骨化纤维瘤。在手术前的生化筛查中,该患者被诊断为原发性甲状旁腺功能亢进。颈部计算机断层扫描显示有一个甲状旁腺肿瘤。进行了手术切除以去除颌骨肿瘤和甲状旁腺腺瘤。术后过程平稳,2年随访未发现复发迹象。在先证者中检测到39delC的HRPT2种系突变,但在其未受影响的父母中未检测到。这些结果表明种系突变是从头发生的。